Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Breast Cancer Reports
Published in: Current Breast Cancer Reports 1/2013

01-03-2013 | Systemic Therapy (J Cortes, Section Editor)

New Microtubule Inhibitors in Breast Cancer

Authors: Cristian B. Villanueva, Fernando F. Bazan, Xavier B. Pivot

Published in: Current Breast Cancer Reports | Issue 1/2013

Login to get access

Abstract

Chemotherapy is still the main basis of treatment of metastatic breast cancer. Antimicrotubule agents regulating polymerization and depolymerization seem to be involved in a crucial physiopathogenic pathway controlling tumor growth. Such agents as paclitaxel and docetaxel have high activity and a survival benefit as first-line treatment for metastatic cancer, but several mechanisms of acquired resistance lead to refractory disease. Finding new active chemotherapeutic agents able to avoid such chemoresistance is a challenge. In this paper we review of the current state of development of new microtubule inhibitors.
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRef
2.
•• Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52. This paper reports new molecular subgroups of breast cancer. PubMed
3.
Rossari JR, Metzger-Filho O, Paesmans M, et al. Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence. J Oncol. 2012;417673.
4.
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520–9.PubMedCrossRef
5.
Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–19.PubMedCrossRef
6.
Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2011;21:242–52.CrossRef
7.
Carrick S, Parker S, Thornton CE et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2009; CD003372.
8.
Fojo T, Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol. 2007;18 Suppl 5:v3–8.PubMedCrossRef
9.
Pivot X, Asmar L, Buzdar AU, et al. A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer. 2000;82:529–34.PubMedCrossRef
10.
• McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008;1785:96–132. This paper focuses on the mechanisms of action of, and resistance to, microtubule inhibitors. PubMed
11.
Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26:1980–6.PubMedCrossRef
12.
Dabydeen DA, Burnett JC, Bai R, et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol. 2006;70:1866–75.PubMedCrossRef
13.
Smith JA, Wilson L, Azarenko O, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry. 2010;49:1331–7.PubMedCrossRef
14.
Okouneva T, Azarenko O, Wilson L, et al. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther. 2008;7:2003–11.PubMedCrossRef
15.
•• Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914–23. This study reported improved overall survival of heavily treated MBC patients after treatment with eribuline. PubMedCrossRef
16.
Goel S, Mita AC, Mita M, et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res. 2009;15:4207–12.PubMedCrossRef
17.
Synold TW, Morgan RJ, Newman EM, et al. A phase I pharmacokinetic, target validation study of the novel anti-tubulin agent E7389: a California Cancer consortium trial. J Clin Oncol. 2005;23.
18.
Tan AR, Rubin EH, Walton DC, et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res. 2009;15:4213–9.PubMedCrossRef
19.
Mukohara T, Nagai S, Mukai H, et al. Eribulin mesylate in patients with refractory cancers: a Phase I study. Investig New Drugs. 2012;30:1926–33.CrossRef
20.
Gupta A, Mould DR, Reyderman L et al. Population pharmacokinetic-pharmacodynamic (PK/PD) analysis of safety and efficacy of eribulin in metastatic or locally advanced breast cancer patients. Abstract presented at the 35th Congress of the European Society for Medical Oncology, Milan, Italy 2010.
21.
Devriese LA, Witteveen PO, Marchetti S, et al. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. Cancer Chemother Pharmacol. 2012;70(6):823–32.PubMedCrossRef
22.
Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2010;28:3922–8.PubMedCrossRef
23.
Vahdat LT, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2009;27:2954–61.PubMedCrossRef
24.
Aogi K, Iwata H, Masuda N, et al. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol. 2012;23:1441–8.PubMedCrossRef
25.
• Kaufman PA, Awada A, Twelves C et al. A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. San Antonio Breast Cancer Symposium 2012 (Abstr S6-6). A new study reported at the 35th SABCS compared eribulin vs capecitabine.
26.
Lockhart AC, Tirona RG, Kim RB. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther. 2003;2:685–98.PubMedCrossRef
27.
Cisternino S, Bourasset F, Archimbaud Y, et al. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood–brain barrier in mice and rats. Br J Pharmacol. 2003;138:1367–75.PubMedCrossRef
28.
Bissery M-C, Bouchard H, Riou JF, et al. Preclinical evaluation of TXD258, a new taxoid. Proc Am Assoc Cancer Res. 2000;41:214. Abstr 1364.
29.
• Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol. 2008;19:1547–52. This is the first phase II study of cabazitaxel in MBC. PubMedCrossRef
30.
• Villanueva C, Awada A, Campone M, et al. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Eur J Cancer. 2011;47:1037–45. This is the second phase II study of cabazitaxel in combination with capecitabine in MBC. PubMedCrossRef
31.
Puglisi F, Cardellino GG, Crivellari D, et al. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer. Ann Oncol. 2008;19:1541–6.PubMedCrossRef
32.
Kurata T, Shimada Y, Tamura T, et al. Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors. J Clin Oncol. 2000;18:3164–71.PubMed
33.
Gelmon KA, Latreille J, Tolcher A, et al. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J Clin Oncol. 2000;18:4098–108.PubMed
34.
Sessa C, Cuvier C, Caldiera S, et al. Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Ann Oncol. 2002;13:1140–50.PubMedCrossRef
35.
Dieras V, Limentani S, Romieu G, et al. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann Oncol. 2008;19:1255–60.PubMedCrossRef
36.
Dieras V, Viens P, Veyret C, et al. Larotaxel (L) in combination with trastuzumab in patients with HER2 + metastatic breast cancer (MBC): interim analysis of an open phase II label study. J Clin Oncol. 2008;26:15s. Abstract 1070.
37.
A randomized, open label, phase 3 study of larotaxel every 3 weeks versus capecitabine in patients with metastatic breast cancer progressing after taxanes and anthracyclines therapy. In Edition 2012.
38.
Shionoya M, Jimbo T, Kitagawa M, et al. DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci. 2003;94:459–66.PubMedCrossRef
39.
Roche M, Kyriakou H, Seiden M. Drug evaluation: tesetaxel–an oral semisynthetic taxane derivative. Curr Opin Investig Drugs. 2006;7:1092–9.PubMed
40.
Tanaka K, Kurata T, Fujisaka Y et al. Pharmacokinetics (PK) and safety of tesetaxel, a novel oral taxane, in Japanese patients (PTS) with advanced solid tumors. Ann Oncol 2012 (abstract 486).
41.
Beeram M, Papadopoulos K, Tolcher AW et al. Tesetaxel: Analysis of two dosing schedules (once weekly vs every 3 weeks) using a novel oral taxane. Ann Oncol 2012; abstract 481p.
42.
Schwartzberg L, Rubin P, Patnaik A, et al. Tesetaxel, an oral taxane as first line therapy for women with metastatic breast cancer. San Antonio Breast Cancer Symposium 2011 (Abstr P5-19-11).
43.
Li C, Wallace S. Polymer-drug conjugates: recent development in clinical oncology. Adv Drug Deliv Rev. 2008;60:886–98.PubMedCrossRef
44.
Lin NU, Parker LM, Come SE, et al. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Investig New Drugs. 2007;25:369–75.CrossRef
45.
Sabbatini P, Aghajanian C, Dizon D, et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol. 2004;22:4523–31.PubMedCrossRef
46.
Campbell RB, Ying B, Kuesters GM, Hemphill R. Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci. 2009;98:411–29.PubMedCrossRef
47.
Treat J, Damjanov N, Huang C, et al. Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. Oncology (Williston Park). 2001;15:44–8.
48.
Thurston G, McLean JW, Rizen M, et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest. 1998;101:1401–13.PubMedCrossRef
49.
Ribeiro JT, Macedo LT, Curigliano G, et al. Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future? Ann Oncol. 2012;23:547–55.PubMedCrossRef
50.
Awada A, Bondarenko IN, Tarasova O, et al. Results of the first randomized phase II study of Cationic Liposomal Paclitaxel (EndoTAGTM-1) targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Ann Oncol. 2010;21(8s):viii5. Abstr LBA12.
51.
Villanueva C, Vuillemin AT, Demarchi M, et al. Ixabepilone: a new active chemotherapy in the treatment of breast cancer. Womens Health (Lond Engl). 2009;5:115–21.CrossRef
52.
Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210–7.PubMedCrossRef
53.
Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010;28:3256–63.PubMedCrossRef
54.
• Pivot XB, Li RK, Thomas ES, et al. Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. Eur J Cancer. 2009;45:2940–6. This study reported the efficacy of ixabepilone against triple-negative breast cancer. PubMedCrossRef
55.
Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25:3407–14.PubMedCrossRef
56.
Rugo HS, Campone M, Amadori D, et al. Randomized phase II study of weekly versus every 3 week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): Final results. J Clin Oncol. 2010;28:15s. suppl; abstr 1040.
57.
• Rugo HS, Barry WT, Moreno-Aspitia A et al. CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2012; 30, 2012 (suppl; abstr CRA1002). This study compared the association of three microtubule inhibitors with bevacizumab.
58.
Fogh S, Machtay M, Werner-Wasik M, et al. Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys. 2010;77:1009–16.PubMedCrossRef
59.
Freedman RA, Bullitt E, Sun L, et al. A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin Breast Cancer. 2011;11:376–83.PubMedCrossRef
60.
Kamath AV, Chang M, Lee FY, et al. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog. Cancer Chemother Pharmacol. 2005;56:145–53.PubMedCrossRef
61.
Murphy C, Nulsen B, Rump M et al. Phase II trial of patupilone in patients with breast cancer brain metastases progressing or recurring after whole brain radiotherapy. ASCO Breast Cancer Symposium 2009; abst 234.
62.
Morrow PK, Divers S, Provencher L, et al. Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy. Breast Cancer Res Treat. 2010;123:837–42.PubMedCrossRef
63.
• Frampton JE, Moen MD. Vinflunine. Drugs. 2010;70:1283–93. This is an extensive review of vinflunine. PubMedCrossRef
64.
Bennouna J, Fumoleau P, Armand JP, et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol. 2003;14:630–7.PubMedCrossRef
65.
Campone M, Isambert N, Bourbouloux E, et al. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol. 2012;69:871–9.PubMedCrossRef
66.
• Fumoleau P, Cortes-Funes H, Taleb AB, et al. Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy. Am J Clin Oncol. 2009;32:375–80. This is an interesting phase II study of vinflunine for previously treated patients with MBC. PubMedCrossRef
67.
Paridaens R, Wildiers H, Dalenc F, et al. Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer. J Clin Oncol. 2007;25(18s):46s. Abstr 1058.
68.
Yardley DA, McCleod M, Schreiber F, et al. A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer. Cancer Investig. 2010;28:925–31.CrossRef
69.
Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454–61.PubMedCrossRef
70.
Oostendorp RL, Witteveen PO, Schwartz B, et al. Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors. Investig New Drugs. 2010;28:163–70.CrossRef
71.
72.
O'Boyle NM, Carr M, Greene LM, et al. Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents. J Med Chem. 2010;53:8569–84.PubMedCrossRef
73.
Blum JL, Savin MA, Edelman G, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer. 2007;7:850–6.PubMedCrossRef
74.
Martin M, Ruiz A, Munoz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol. 2007;8:219–25.PubMedCrossRef
75.
Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004;40:536–42.PubMedCrossRef
76.
Barrios CH, Liu MC, Lee SC, et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat. 2010;121:121–31.PubMedCrossRef
77.
Keller AM, Mennel RG, Georgoulias VA, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol. 2004;22:3893–901.PubMedCrossRef
Metadata
Title
New Microtubule Inhibitors in Breast Cancer
Authors
Cristian B. Villanueva
Fernando F. Bazan
Xavier B. Pivot
Publication date
01-03-2013
Publisher
Current Science Inc.
Published in
Current Breast Cancer Reports / Issue 1/2013
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-012-0101-9

Other articles of this Issue 1/2013

Current Breast Cancer Reports 1/2013 Go to the issue

Systemic Therapy (J Cortes, Section Editor)

Update on the Role of Epothilones in Metastatic Breast Cancer

Systemic Therapy (J Cortes, Section Editor)

The Future of Chemotherapy in the Era of Personalized Medicine

Systemic Therapy (J Cortes, Section Editor)

The Role of Liposomal Anthracyclines in Metastatic Breast Cancer

Systemic Therapy (J Cortes, Section Editor)

Topoisomerase Inhibitors in Metastatic Breast Cancer: Overview of Current Practice and Future Development

Systemic Therapy (J Cortes, Section Editor)

The Role of Platinum Compounds for the Treatment of Breast Cancer

Systemic Therapy (J Cortes, Section Editor)

Chemotherapy in Patients with Anthracycline and Taxane-Pretreated Metastatic Breast Cancer: An Overview
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits